Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ Formula in mild to moderate COVID-19
NCT04914377Phase 2Completed
- Sponsor
- Novatek Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Drug Delivery Systems, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing TQ Formula with Placebo (2 arms). Primary endpoints: Median Time to Sustained Clinical Response at 21 days and Number and Percentage of Participants With Overall Adverse Events at 45 days. Started Jun 2021; status: completed.
02
Drugs
NP-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04914377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914377.